Canada markets closed

Canntab Therapeutics Limited (CTABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8166-0.0327 (-3.85%)
At close: 3:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8493
Open0.8125
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7982 - 0.8250
52 Week Range0.3480 - 0.8940
Volume9,019
Avg. Volume7,171
Market Cap28.799M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.0780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 08, 2016
1y Target EstN/A
  • Canntab Receives Export License Approval from Health Canada
    CNW Group

    Canntab Receives Export License Approval from Health Canada

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.

  • Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
    CNW Group

    Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia

    * 3rd Patent Grant with Australia following the United States and Canada * Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited * Participation in Australia's Largest Cannabis Research StudyTORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No.

  • Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
    Newsfile

    Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.

    Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape ...